Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
ASKA Extends Relugolix Combo Deal with Takeda into Endometriosis
ASKA Pharmaceutical said on May 31 that it has additionally obtained the exclusive development and marketing rights to Takeda Pharmaceutical’s combination drug containing relugolix, estradiol, and norethindrone acetate in Japan for the treatment of endometriosis. In September 2021, the two…
To read the full story
Related Article
- ASKA’s Relugolix Combo Hits Primary Goal in Japan PIII Fibroid Study
June 23, 2026
- ASKA Launches Japan PIII of Relugolix Combo for Endometriosis
June 26, 2025
- ASKA Begins Japan PIII for Relugolix Combo Drug
December 17, 2024
- ASKA Begins Japan PI/II for Relugolix Combo Drug
July 21, 2023
- ASKA Earns Japan Rights to Takeda’s Relugolix Combo Drug
September 28, 2021
- Relumina Submitted for Endometriosis Use in Japan: ASKA
January 29, 2021
- Relugolix Nets Positive PIII Data in Endometriosis, ASKA Set to Seek Add’l Use in H1 2021
November 26, 2020
- ASKA Takes Over Uterine Fibroids Drug Relumina from Takeda
February 18, 2020
- Takeda Licenses Relugolix to ASKA in Women’s Health Field
June 1, 2018
BUSINESS
- Average Pay at 21 Japan Drug Makers Up 3.8%, Chugai Tops 13 Million Yen
July 2, 2026
- Mochida Seeks Pediatric Expansion for Urece
July 2, 2026
- Kowa Files US NDA for Nicox’s Glaucoma Drug
July 2, 2026
- GNI Closes Acquisition of Ayumi Pharma
July 2, 2026
- Toho to Acquire Ishin Pharma, Bring Allostem Distribution In-House
July 2, 2026
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…